Peptides for assisting delivery across the blood brain barrier

Patent metadata

Field	Value
Publication number	US-9757470-B2
Application number	US-201414265939-A
Country	US
Kind code	B2
Filing date	Apr 30, 2014
Priority date	May 22, 2006
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.

First claim

The invention claimed is:

1. A chimeric peptide comprising the amino acid sequence of SEQ ID NO: 13 and a cell permeable peptide.

2. The chimeric peptide of claim 1 , wherein the cell permeable peptide is located at the C-terminus of SEQ ID NO: 13.

3. The chimeric peptide of claim 1 , wherein the cell permeable peptide is selected from the group consisting of SEQ ID NO: 1-12, and 17-32.

4. The chimeric peptide of claim 1 , wherein the cell permeable peptide is a polymer consisting of arginine residues.

5. The chimeric peptide of claim 4 , wherein the number of the arginine residues in the polymer ranges from about 3 to about 11 residues.

6. The chimeric peptide of claim 5 , wherein at least one of the arginine residues is a D-arginine isomer.

7. The chimeric peptide of claim 1 , wherein the cell permeable peptide is a protamine peptide.

8. The chimeric peptide of claim 1 , wherein the chimeric peptide is selected from the group consisting of SEQ ID NO: 14, 15, 16, and 34.

9. A composition for targeted delivery to neuronal cells comprising at least one chimeric peptide of claim 1 and at least one effector agent.

10. The composition of claim 9 , wherein the at least one effector agent comprises a nucleic acid for the targeted delivery of the nucleic acid into neuronal cells.

11. The composition of claim 10 , wherein the nucleic acid is an siRNA or a viral vector DNA.

12. The composition of claim 9 , wherein the at least one effector agent is a therapeutic agent for the targeted delivery of the therapeutic agent into neuronal cells.

13. The composition of claim 9 , wherein the at least one effector agent is a diagnostic agent or imaging agent for the targeted delivery of the diagnostic or imaging agent into neuronal cells.

14. A method of targeted delivery to neuronal cells comprising contacting the cells with at least one chimeric peptide of claim 1 or a composition comprising at least one chimeric peptide of claim 1 .

15. A synthetic peptide comprising SEQ ID NO: 34.

16. The synthetic peptide of claim 15 , prepared as a dry powder.

Assignees

• Children'S Medical Center Corp

Inventors

• Narasimhaswamy Manjunath
• Shankar Premlata
• Kumar Priti

Classifications

• A61K47/48969

  Human Necessities · mapped topic

• A61K47/48238

  Human Necessities · mapped topic

• A61K47/48815

  Human Necessities · mapped topic

• B82Y5/00 Primary

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K47/48246 Primary

  Human Necessities · mapped topic